SCHEMBL6907702

SCHEMBL6907702

COc1ccc(OC[C@H]2O[C@H](n3cnc4c(N)ncnc43)[C@H](O)[C@H]2O)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
METTL3 Q86U44 1/20 0.70
ADORA1 P30542 5/20 0.66
SMN1; SMN2 Q16637 3/20 0.66
ADORA3 P0DMS8 2/20 0.66
ADORA2A P29274 2/20 0.66
ADORA2B P29275 2/20 0.66
DPP4 P27487 1/20 0.66
MEN1 O00255 1/20 0.66
SLC28A1 O00337 1/20 0.66
MAP3K7 O43318 1/20 0.66
SLC28A2 O43868 1/20 0.66
GAPDH P04406 1/20 0.66
MAPK1 P28482 1/20 0.66
STAT6 P42226 1/20 0.66
PI4KA P42356 1/20 0.66
KMT2A Q03164 1/20 0.66
PI4K2B Q8TCG2 1/20 0.66
DOT1L Q8TEK3 1/20 0.66
SLC29A1 Q99808 1/20 0.66
PI4K2A Q9BTU6 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8623694 0.91 METTL3 (0.59) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL6905464 0.90 ADORA1 (0.72) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL1434032 0.90 ADORA1 (0.72) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL4537888 0.89 TRDMT1 (0.64) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL5276197 0.89 TRDMT1 (0.60) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL13268788 0.88 PRKAG1 (0.60) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL13268853 0.88 PRKAG1 (0.60) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL337873 0.88 ABCB1 (0.75) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B
SCHEMBL13269145 0.88 PRKAG1 (0.60) METTL3ADORA1SMN1; SMN2ADORA3ADORA2A
SCHEMBL15338536 0.87 ADORA1 (0.74) ADORA1SMN1; SMN2ADORA3ADORA2AADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells AGOURON PHARMACEUTICALS INC. 2004-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043959-A1 Combination therapies for treating methylthioadenosine phosphorylase deficient cells APRT, MTAP, TYMP METTL3 132/4885ADORA1 858/4885SMN1; SMN2 1993/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.